IP Library › Patent Application 18135823
Patent Application
App. No. 18/135,823

METHODS OF TREATING HEPATIC ENCEPHALOPATHY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/135,823
Abstract

The application describes treatment of hepatic encephalopathy using gastrointestinal specific antibiotics. One example of a gastrointestinal specific antibiotic is rifaximin.

Claims (9)

1 - 96 . (canceled)

97 . A method of reducing a cirrhosis subject's risk of experiencing a breakthrough overt hepatic encephalopathy (HE) episode, comprising administering to the cirrhosis subject 550 mg of rifaximin.

98 . The method of claim 97 , further comprising administering lactulose.

99 . The method of claim 97 , wherein the subject has a Model for End-Stage Liver Disease (MELD) level between 1 and 24.

100 . The method of claim 97 , wherein the subject has a Model for End-Stage Liver Disease (MELD) level less than or equal to ten.

101 . The method of claim 97 , wherein the subject has a Model for End-Stage Liver Disease (MELD) level between 11 and 18.

102 . The method of claim 97 , wherein the subject has a Model for End-Stage Liver Disease (MELD) level between 19 and 24.

103 . The method of claim 97 , wherein the subject has a Conn score of 0 or 1.

104 . The method of claim 97 , wherein the subject is administered 550 mg of rifaximin two times per day (BID).

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 25, 2023
From: BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL, INC.
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 064719/0004 →
SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 25, 2023
From: BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 064719/0013 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 25, 2023
From: BAUSCH HEALTH IRELAND LIMITED; SALIX PHARMACEUTICALS, INC.; SOLTA MEDICAL, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 064719/0022 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2023
From: FORBES, WILLIAM
To: SALIX PHARMACEUTICALS, LTD.
Reel/Frame 063359/0480 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2023
From: SALIX PHARMACEUTICALS, LTD.
To: SALIX PHARMACEUTICALS, INC.
Reel/Frame 063359/0517 →